Resilience is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. They are focused on creating processes and platforms to enable scientists to make novel therapies quickly, safely, and at scale.

Ology Bioservices, Inc.

Therapure Biopharma Inc

Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. 

U.S. Department of Defense

U.S. International Development Finance Corp

Mubadala

Magnetic Ventures

ARCH Venture Partners

Google Ventures

Lux Capital

New Enterprise Associates

Resilience

When your need for larger-scale vaccine production outgrows your cell stacks or flasks, there is a clear and easy path to scale up and maximize your yields. 

Learn how our team of process development experts and proprietary Vero and Quail cell lines can support the development of your vaccine with Path-to-PAD (Process and Analytical Development) in our latest blog post: https://hubs.ly/Q02l0J9Q0 

#Development #Vaccine #CellLine

On #RareDiseaseDay, Resilience joins the rare disease community in advocating for people and families living with rare diseases. 
 
We are honored to partner with @BridgeBio, as together we remain dedicated to accelerating the development of innovative therapies for families living with Canavan disease and congenital adrenal hyperplasia.
 
Learn more:https://hubs.ly/Q02m7gP00

Drug Development & Delivery recently interviewed Resilience Chief Commercial Officer Syed T. Husain about how Resilience was built to revolutionize the CDMO space with a refocus on the foundations of biomanufacturing, a reprioritization on manufacturing technology development, and a redefinition of partnership. Read the full article: https://hubs.ly/Q02kTsdy0 

DCAT Week 2024 is just around the corner – make the most of your time in New York City by securing a meeting with Resilience. Request a meeting: https://hubs.ly/Q02m5z6x0 

#DCATWeek


The need for advanced technology platforms that offer a clear, end-to-end path to commercial manufacturing is driving biotech companies to outsource critical stages of their biomanufacturing processes.

Our recent whitepaper, "The Stage-Gate Model: A Value-Driven Approach to Accelerate Biomanufacturing," highlights how to perform critical activities leveraging process and analytical development resources from early-stage clinical to commercialization: https://hubs.ly/Q02hyVMH0

#biomanufacturing #techtransfer #processdevelopment #analyticaldevelopment #resilience

COM:RESILIENCE

Resilience

Analysis Not Available